Patents by Inventor Donald C. Foster
Donald C. Foster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5905185Abstract: Methods for producing protein C in transgenic non-human mammals are disclosed. The protein C is modified at the two-chain cleavage site between the light and heavy chains of protein C from Lys-Arg to R.sub.1 -R.sub.2 -R.sub.3 -R.sub.4 where R.sub.1 through R.sub.4 are individually Arg or Lys. DNA segments encoding modified protein C are introduced into the germ line of a non-human mammals, and the mammal or its female progeny produces milk containing protein C expressed from the introduced DNA segments. The protein C expressed from the introduced DNA segments has anticoagulant activity when activated. Non-human mammalian embryos and transgenic non-human mammals carrying DNA segments encoding heterologous protein C are also disclosed.Type: GrantFiled: November 26, 1996Date of Patent: May 18, 1999Assignees: PPL Therapeutics, ZymoGenetics, Inc.Inventors: Ian Garner, Ian R. Cottingham, Simon M. Temperley, Donald C. Foster, Cindy A. Sprecher, Donna E. Prunkard
-
Patent number: 5792620Abstract: Human pancreatic islet cell glutamic acid decarboxylase (GAD), an autoantigen involved in the development of insulin-dependent diabetes mellitus (IDDM), has been cloned, sequenced and expressed by recombinant means. Recombinant human islet cell GAD polypeptides and antibodies specific to the GAD polypeptides can be used in methods of diagnosis and treatment, including use in immunoadsorptive therapy and the induction of immune tolerance.Type: GrantFiled: August 17, 1993Date of Patent: August 11, 1998Assignees: The Board of Regents of the University of Washington, ZymoGenetics, Inc.Inventors: Ake Lernmark, Allan E. Karlsen, Catherine E. Grubin, William Hagopian, Patrick J. O'Hara, Donald C. Foster
-
Patent number: 5792850Abstract: Novel receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise an extracellular ligand-binding domain of a cell-surface receptor that is expressed at high levels in lymphoid tissue, including B-cells and T-cells. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo.Type: GrantFiled: May 23, 1996Date of Patent: August 11, 1998Assignee: ZymoGenetics, Inc.Inventors: James W. Baumgartner, Donald C. Foster, Frank J. Grant, Cindy A. Sprecher
-
Patent number: 5776725Abstract: The present invention provides isolated DNA molecules comprising a DNA segment encoding a glucagon receptor. Also provided are DNA constructs comprising a first DNA segment encoding a glucagon receptor operably linked to additional DNA segments required for the expression of the first DNA segment, as well as host cells containing such DNA constructs.Type: GrantFiled: July 1, 1993Date of Patent: July 7, 1998Assignee: ZymoGenetics, Inc.Inventors: Wayne R. Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, Francis J. Grant, Joseph L. Kuijper, Donald C. Foster, Si Lok, Patrick J. O'Hara
-
Patent number: 5770445Abstract: The present invention provides isolated DNA molecules comprising a DNA segment encoding a glucagon receptor. Also provided are DNA constructs comprising a first DNA segment encoding a glucagon receptor operably linked to additional DNA segments required for the expression of the first DNA segment, as well as host cells containing such DNA constructs.Type: GrantFiled: May 30, 1995Date of Patent: June 23, 1998Assignee: ZymoGenetics, Inc.Inventors: Wayne R. Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, Francis J. Grant, Joseph L. Kuijper, Donald C. Foster, Si Lok, Patrick J. O'Hara
-
Patent number: 5766921Abstract: Human protein C molecules are modified to provide increased resistance to inactivation by human plasma factors while retaining substantially the biological activity of human protein C. The modifications are generally to the heavy chain of protein C, which chain may be substituted with a protein C heavy chain of non-human origin, such as bovine, yielding a chimeric protein C molecule. The human protein C heavy chain may also be modified to be human-like, in that at least one amino acid from a non-human sequence may be substituted for the corresponding residue(s) of the human sequence, thereby allowing the molecule to retain substantially human characteristics yet having increased resistance to inactivation. Also included are methods for producing the modified protein C molecules and pharmaceutical compositions thereof.Type: GrantFiled: October 5, 1994Date of Patent: June 16, 1998Assignee: Zymogenetics, Inc.Inventors: Donald C. Foster, Richard D. Holly
-
Patent number: 5753224Abstract: Human protein C molecules are modified to provide increased resistance to inactivation by human plasma factors while retaining substantially the biological activity of human protein C. The modifications are generally to the heavy chain of protein C, which chain may be substituted with a protein C heavy chain of non-human origin, such as bovine, yielding a chimeric protein C molecule. The human protein C heavy chain may also be modified to be human-like, in that at least one amino acid from a non-human sequence may be substituted for the corresponding residue(s) of the human sequence, thereby allowing the molecule to retain substantially human characteristics yet having increased resistance to inactivation. Also included are methods for producing the modified protein C molecules and pharmaceutical compositions thereof.Type: GrantFiled: June 5, 1995Date of Patent: May 19, 1998Assignee: ZymoGenetics, Inc.Inventors: Donald C. Foster, Richard D. Holly
-
Patent number: 5728674Abstract: The present invention provides isolated DNA molecules comprising a DNA segment encoding novel human Kunitz-type inhibitors. Also provided are DNA constructs comprising a first DNA segment encoding a novel human Kunitz-type inhibitor wherein said first DNA segment is operably linked to additional DNA segments required for the expression for the first DNA segment, as well as host cells containing such DNA constructs and methods for producing proteins from the host cells.Type: GrantFiled: June 1, 1995Date of Patent: March 17, 1998Assignee: ZymoGenetics, Inc.Inventors: Cindy A. Sprecher, Walt Kisiel, Donald C. Foster
-
Patent number: 5677146Abstract: The present invention provides isolated DNA molecules comprising a DNA segment encoding a novel human amyloid protein precursor homologue and novel Kunitz-type inhibitors. Also provided are DNA constructs comprising a first DNA segment encoding a novel human amyloid protein precursor homologue or a novel Kunitz-type inhibitor wherein said first DNA segment is operably linked to additional DNA segments required for the expression for the first DNA segment, as well as host cells containing such DNA constructs and methods for producing proteins from the host cells.Type: GrantFiled: April 18, 1995Date of Patent: October 14, 1997Assignee: Zymogenetics, Inc.Inventors: Cindy A. Sprecher, Donald C. Foster, Kjeld E. Norris
-
Patent number: 5641655Abstract: DNA constructs useful in the production of thrombopoietin are disclosed. In general, the DNA constructs comprise a first DNA segment encoding a fusion of an amino-terminal secretory peptide joined to a thrombopoietin polypeptide and one or more additional DNA segments that provide for the transcription of the first segment. The secretory peptide is a native mammalian t-PA secretory peptide or may be modified to enhance proteolytic cleavage of the fusion. Also disclosed are cultured eukaryotic cells containing these DNA constructs and methods for producing thrombopoietin polypeptides through the use of the DNA constructs and cultured eukaryotic cells.Type: GrantFiled: November 30, 1994Date of Patent: June 24, 1997Assignee: ZymoGenetics, Inc.Inventors: Donald C. Foster, Mark D. Heipel, Richard D. Holly
-
Patent number: 5639940Abstract: Materials and methods for producing fibrinogen in transgenic non-human mammals are disclosed. DNA segments encoding A.alpha., B.beta. and .gamma. chains of fibrinogen are introduced into the germ line of a non-human mammal, and the mammal or its female progeny produces milk containing fibrinogen expressed from the introduced DNA segments. Non-human mammalian embryos and transgenic non-human mammals carrying DNA segments encoding heterologous fibrinogen polypeptide chains are also disclosed.Type: GrantFiled: March 3, 1994Date of Patent: June 17, 1997Assignees: Pharmaceutical Proteins Ltd., ZymoGenetics, Inc.Inventors: Ian Garner, Michael L. Dalrymple, Donna E. Prunkard, Donald C. Foster
-
Patent number: 5620132Abstract: The present invention relates generally to a new apparatus and method for removing solid material and liquid material that may contain solid material from a substrate. More particularly, the invention encompasses an apparatus and method for removing molten solder which may contain solid particles and solder balls or columns from a substrate using a unique squeegee. Also, disclosed is a method for removing solder balls or columns from a substrate using a backer having an adhesive thereon.Type: GrantFiled: June 5, 1995Date of Patent: April 15, 1997Assignee: International Business Machines CorporationInventors: Andrew J. Downing, Donald C. Foster, Karl J. Puttlitz
-
Patent number: 5618696Abstract: The present invention relates to a human Kunitz-type protease inhibitor comprising the following amino acid sequenceAsp Leu Leu Pro Asn Val Cys Ala Phe Pro Met Glu Lys Gly Pro Cys Gln Thr Tyr Met Thr Arg Trp Phe Phe Asn Phe Glu Thr Gly Glu Cys Glu Leu Phe Ala Tyr Gly Gly Cys Gly Gly Asn Ser Asn Asn Phe Leu Arg Lys Glu Lys Cys Glu Lys Phe Cys Lys Phe Thr(SEQ ID NO:1)or a variant thereof with protease inhibitor properties.Type: GrantFiled: February 6, 1995Date of Patent: April 8, 1997Assignee: Novo Nordisk A/SInventors: Fanny Norris, Kjeld Norris, S.o slashed.ren E. Bj.o slashed.rn, Lars C. Petersen, Ole H. Olsen, Donald C. Foster, Cindy A. Sprecher
-
Patent number: 5527692Abstract: Methods are disclosed for producing thrombin. The protein is produced from host cells transformed or transfected with DNA construct(s) containing information necessary to direct the expression of thrombin precursors. The DNA constructs generally include the following operably linked elements: a transcriptional promoter, DNA sequence encoding a gla-domainless prothrombin, and a transcriptional terminator. Thrombin precursors produced from transformed or transfected host cells are activated either in vivo or in vitro.Type: GrantFiled: June 5, 1995Date of Patent: June 18, 1996Assignee: Zymogenetics, Inc.Inventors: Richard D. Holly, Donald C. Foster
-
Patent number: 5516650Abstract: Methods are disclosed for producing a protein which has substantially the same biological activity as human protein C or human activated protein C. The protein is produced by mammalian host cells transfected with a plasmid capable of integration in mammalian host cell DNA. The plasmid includes a promoter followed downstream by a nucleotide sequence which encodes a protein having substantially the same structure and/or activity as human protein C or human activated protein C the nucleotide sequence being followed downstream by a polyadenylation signal.Type: GrantFiled: April 8, 1994Date of Patent: May 14, 1996Assignee: Zymogenetics, Inc.Inventors: Donald C. Foster, Mark J. Murray, Kathleen L. Berkner
-
Patent number: 5504001Abstract: Hybrid proteins comprising a cross-linking domain derived from a protein that acts as an acyl-donor substrate for factor XIIIa, a fibrin-binding domain, and a serine protease domain are disclosed. Host cells transfected or transformed with an expression vector comprising a transcriptional promoter operably linked to a DNA sequence encoding such hybrid proteins are also disclosed, as well as methods for producing the proteins. The proteins may be utilized in combination with a suitable carrier or diluent as pharmaceutical compositions.Type: GrantFiled: June 6, 1994Date of Patent: April 2, 1996Assignee: ZymoGenetics, Inc.Inventor: Donald C. Foster
-
Patent number: 5502034Abstract: Methods are disclosed for producing thrombin. The protein is produced from host cells transformed or transfected with DNA construct(s) containing information necessary to direct the expression of thrombin precursors. The DNA constructs generally include the following operably linked elements: a transcriptional promoter, DNA sequence encoding a gla-domainless prothrombin, and a transcriptional terminator. Thrombin precursors produced from transformed or transfected host cells are activated either in vivo or in vitro.Type: GrantFiled: June 5, 1995Date of Patent: March 26, 1996Assignee: Zymogenetics, Inc.Inventors: Richard D. Holly, Donald C. Foster
-
Patent number: 5476777Abstract: Methods are disclosed for producing thrombin. The protein is produced from host cells transformed or transfected with DNA construct(s) containing information necessary to direct the expression of thrombin precursors. The DNA constructs generally include the following operably linked elements: a transcriptional promoter, DNA sequence encoding a gla-domainless prothrombin, and a transcriptional terminator. Thrombin precursors produced from transformed or transfected host cells are activated either in vivo or in vitro.Type: GrantFiled: December 30, 1992Date of Patent: December 19, 1995Assignee: Zymogenetics, Inc.Inventors: Richard D. Holly, Donald C. Foster
-
Patent number: 5458281Abstract: The present invention relates generally to a new apparatus and method for removing solid material and liquid material that may contain solid material from a substrate. More particularly, the invention encompasses an apparatus and method for removing molten solder which may contain solid particles and solder balls or columns from a substrate using a unique squeegee. Also, disclosed is a method for removing solder balls or columns from a substrate using a backer having an adhesive thereon.Type: GrantFiled: June 30, 1994Date of Patent: October 17, 1995Assignee: International Business Machines CorporationInventors: Andrew J. Downing, Donald C. Foster, Karl J. Puttlitz
-
Patent number: 5455338Abstract: The present invention provides isolated DNA molecules comprising a DNA segment encoding novel human Kunitz-type inhibitors. Also provided are DNA constructs comprising a first DNA segment encoding a novel human Kunitz-type inhibitor wherein said first DNA segment is operably linked to additional DNA segments required for the expression for the first DNA segment, as well as host cells containing such DNA constructs and methods for producing proteins from the host cells.Type: GrantFiled: November 5, 1993Date of Patent: October 3, 1995Assignees: ZymoGenetics, Inc., University of New MexicoInventors: Cindy A. Sprecher, Walt Kisiel, Donald C. Foster